A brief overview of surgery for atrial fibrillation by Cox, James L
© AME Publishing Company. All rights reserved. Ann Cardiothorac Surg 2014;3(1):80-88www.annalscts.com
Several surgical approaches were developed in the 1980s to 
treat atrial fibrillation (AF), including the left atrial isolation 
procedure [1980] (1), the corridor procedure [1985] (2), the 
atrial transection procedure [1986] (3), the Maze procedure 
[1987] (4,5) and the radial procedure [1989] (6). The first 
two were designed to isolate the arrhythmia to one particular 
region of the atrium rather than to ablate the AF. The last 
three were designed to ablate the arrhythmia itself, but only 
the Maze procedure proved to be successful over time (7-10). 
The electrophysiologic basis of AF and the Maze 
procedure
The Maze procedure was based not only on previous 
concepts introduced by Gordon Moe in the early 1960s 
(11,12) and confirmed by Allessie’s group experimentally in 
the 1980s (13,14), but also on our own extensive multi-point 
computerized mapping of AF in experimental models and 
in patients with AF (15). We documented that all AF, once 
induced, is characterized by the presence of two or more 
large macro-reentrant circuits in the atria simultaneously. 
We then deduced that by placing atrial lesions close enough 
together, these large macro-reentrant circuits could not 
form and therefore, the atria could not fibrillate (4). We 
were aware that one way to accomplish this goal was to 
“breadloaf” the atria into small, isolated strips of tissue, 
but that would preclude the ability to activate the atria 
during any subsequent postoperative sinus rhythm. Thus, 
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the dilemma was how to prevent atrial macro-reentry with 
surgical lesions and still leave the atria capable of resuming 
a normal sinus rhythm (NSR) with restoration of atrial 
transport function. We determined that the only method 
of accomplishing both goals, AF ablation and a return of 
NSR, was to place the lesions in the atria in the pattern of 
a maze, in which the lesions were close enough together to 
prevent atrial macro-reentry but would allow a sinus node 
impulse to activate the majority of both atria and to reach 
the ventricles via the AV node.
While we were successful  in  documenting the 
electrophysiologic characteristics of established AF 
(15-17), we were never able to capture the spontaneous 
onset of an episode of AF. It remained for Haissaguerre 
to demonstrate that AF episodes are induced by focal 
triggers in the atria, an observation that he first reported in 
1998 (18). Haissaguerre noted that 90% of these triggers 
were located in and around the orifices of the pulmonary 
veins, and that the remaining 10% were located in other 
sites such as the right atrium, the crista terminalis, and the 
left atrial appendage, etc. Haissaguerre’s paper resulted in 
an explosion of new efforts by cardiologists and surgeons 
worldwide to cure AF by catheter ablation and new surgical 
techniques, respectively. This intense activity was largely 
based on an over-reading of Haissaguerre’s findings to 
mean that all one had to do to cure AF was to isolate the 
pulmonary veins. This oversimplification of Haissaguerre’s 
findings resulted in the creation of an entirely new industry 
for the development of multiple types of ablation catheters, 
surgical devices and new energy sources, all of which were 
originally designed to isolate the pulmonary veins.
While Haissaguerre’s seminal paper has resulted in 
millions of patients with AF receiving better care, only 
about 60% of all AF (paroxysmal AF) is caused by these 
atrial triggers. The other 40% or so of AF (non-paroxysmal 
AF) is due to well-established self-perpetuating macro-
reentrant circuits that have little or nothing to do with 
these focal pulmonary vein triggers. Furthermore, the 
catheter mapping that was performed by Haissaguerre 
and by subsequent interventional electrophysiologists was 
performed in patients with so-called “stand-alone” AF, i.e., 
with AF that is not associated with other cardiac disease 
that is significant to warrant surgery. Since surgeons deal 
primarily with AF that is secondary to left heart problems 
such as mitral valve disease, aortic valve disease, coronary 
artery disease and heart failure, Haissaguerre’s observation 
that virtually all paroxysmal atrial fibrillation (PAF) is due 
to pulmonary vein triggers may not be applicable in these 
surgical patients. No analysis of the distribution of AF 
triggers in the atria has been performed for patients who 
have so-called “concomitant AF” with which surgeons must 
deal. Therefore, simple pulmonary vein isolation for PAF 
may not be as effective in surgical patients with concomitant 
PAF as it is in non-surgical patients with Stand-Alone PAF.
Because of atrial remodeling (19), which often occurs 
after many years of PAF, the macro-reentrant circuits of 
AF can eventually become self-perpetuating. When this 
occurs, what were once only temporary episodes of AF can 
become long-standing or even permanent. At that point 
the patient has non-paroxysmal atrial fibrillation (N-PAF) 
and the underlying electrophysiologic culprit is no longer 
the focal atrial triggers but rather, the macro-reentrant 
circuits themselves. In these patients, simple isolation of the 
pulmonary veins is no longer an effective treatment because 
the triggers have little to do with the arrhythmia. In these 
patients, it is necessary to place additional linear lesions in 
the atria to interrupt the culprit macro-reentrant circuits. 
Thus, for interventional purposes, AF need be divided 
into only two categories: PAF and N-PAF. The universally 
accepted AHA/ACC/ESC classification of AF includes 
paroxysmal AF, persistent AF and long-standing persistent 
AF. However, since both persistent AF and long-standing 
persistent AF are dependent primarily upon macro-reentry, 
not atrial triggers, they should be treated the same way 
interventionally. In the more practical “Interventional 
Classification of AF”, persistent AF and long-standing 
persistent AF are combined into the category of N-PAF.
This concept of the electrophysiology of AF has 
been challenged for decades, primarily by interventional 
electrophysiologists, and continues to be the only significant 
controversy surrounding the interventional treatment 
(catheter ablation or surgery) of AF (20). All parties agree 
that individual episodes of AF are induced by focal triggers 
as defined by Haissaguerre. However, most interventional 
electrophysiologists and many surgeons also believe that 
the mechanisms responsible for maintaining AF are focal 
and therefore, that even patients with N-PAF can be treated 
successfully by ablation of these focal sites (21-25). The one 
observation that ultimately refutes this concept is the fact 
that the Maze procedure is extremely effective in ablating 
AF (7-10). If N-PAF were maintained by focal abnormalities 
it would be impossible for the Maze procedure to work…
ever! To address this obvious problem, some argue that the 
focal sites that supposedly maintain N-PAF are located in 
and around the pulmonary veins, much like the triggers that 
induce AF, and that they are inadvertently isolated as a part 
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of the Maze procedure, explaining why the Maze procedure 
is effective in N-PAF. If this were the case, however, 
isolation of the pulmonary veins would be just as effective 
for N-PAF as it is for PAF and that is demonstrably not the 
case (26-29)!
Recently, there have been numerous publications 
suggesting that both PAF and N-PAF can be treated 
successfully by local ablation techniques if sophisticated 
mapping is available (24,25,30). Certainly, there are 
some cases in which this is true. However, the question 
revolves around the percentage of patients who have such 
focal sites that drive and maintain AF. If a significant 
percentage of patients had AF that was driven by these 
focal mechanisms, the Maze procedure would have proven 
to be a dismal failure rather than evolving into the so-
called “gold standard” for the interventional treatment of 
AF (31,32). Thus, we remain convinced that all one needs 
to understand to treat AF successfully by interventional 
means is the following: (I) stand-alone PAF is caused by 
focal atrial triggers and can be treated satisfactorily in most 
patients by isolating the pulmonary veins, with the caveat 
that pulmonary vein isolation alone may be somewhat 
less successful for concomitant PAF; and (II) all N-PAF 
(persistent and long-standing persistent AF), whether stand-
alone or concomitant, requires additional linear lesions 
to accompany pulmonary vein isolation in order to attain 
lasting results.
Why concomitant AF should be treated?
Though it is impossible to know the precise numbers 
involved, the best estimates are that of all the patients 
undergoing cardiac surgery in the U.S. each year, some 
81,000 of them have a history of AF or are actually in AF 
at the time of surgery. Of these, only some 21,000 receive 
an additional surgical procedure specifically for AF in 
addition to their primary procedure (33). This means that 
the concomitant problem of AF is simply ignored in 3 out 
of every 4 cardiac surgical patients. 
In 2010, an independent survey was conducted at the 
annual meeting of the American Association for Thoracic 
Surgery (AATS) to determine why most U.S. cardiac 
surgeons simply ignore the opportunity to treat AF in 
patients who are already going to be in their operating 
rooms for some other cardiac procedure (34). The 
overwhelming response was that surgeons were concerned 
that adding an AF procedure, such as pulmonary vein 
isolation or a Maze procedure, to the primary procedure 
would add too much risk. Ad and colleagues subsequently 
addressed this concern in a study of patients undergoing 
aortic valve replacement (AVR) or coronary artery bypass 
surgery (CABG) (35). Their conclusions were that adding a 
Maze procedure to the primary procedure did not increase 
the risk of surgery and that in fact, those patients who had 
the additional Maze procedures actually seemed to do better 
than those patients in whom AF was simply ignored.
Another concern was that surgeons who were in strictly 
private practices away from major medical centers might 
not be able to attain the same results for AF surgery that 
are achieved by surgeons in larger or more academic 
environments. Implicit in this concern was the suspicion 
that it simply might not matter whether or not the AF was 
addressed at the time of surgery for other cardiac problems. 
However, the surgical literature clearly documents the 
advantages of treating concomitant AF rather than ignoring 
it. Those documented advantages include enhancing the 
return of sinus rhythm postoperatively (36), an improved 
quality of life (37), less postoperative tricuspid insufficiency (38), 
decreasing the incidence of long-term strokes (39,40), fewer 
valve-related complications (40), and improved long-term 
survival (41).
Finally, the survey showed that surgeons seem confused 
in their perception that the leading societies in cardiac 
surgery and cardiology cannot agree on recommendations 
regarding how to handle concomitant AF. This is only 
partially true in that these societies have not yet agreed 
on exactly what should be done to treat the concomitant 
AF, i.e., which specific AF procedure to use, etc. However, 
the notion that these societies are unclear on whether 
or not concomitant AF should be treated at all is simply 
not accurate. A 2012 consensus statement on the surgical 
treatment of AF states: “It is advisable that all patients with 
documented AF referred for other cardiac surgeries undergo a 
left or biatrial procedure for AF at an experienced center, unless 
it…will add significant risk…” (42). The organizations 
that formed this consensus included the Heart Rhythm 
Society, the American College of Cardiology, the American 
Heart Association, the Society of Thoracic Surgeons, the 
European Heart Rhythm Association and the European 
Cardiac Arrhythmia Society. In addition, the International 
Society of Minimally Invasive Cardiac Surgery produced a 
similar statement in 2012 that reads: “Concomitant surgical 
ablation is recommended…to increase the incidence of sinus 
rhythm both at short- and long-term follow-up… to improve 
ejection fraction and exercise tolerance…to reduce the risk of 
stroke and thromboembolic events…and to improve long-term 
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survival.” (43). Thus, it is clear that the authorities in both 
cardiology and cardiac surgery believe that concomitant AF 
should be treated whenever possible.
How to treat concomitant AF
Only three groups of patients with concomitant AF will 
be addressed because these three groups represent the vast 
majority of patients who undergo cardiac surgery:
(I) Patients undergoing CABG;
(II) Patients undergoing AVR;
(III) Patients undergoing mitral valve replacement or 
repair.
One of the most common questions asked by surgeons is, 
“Are the right atrial lesions really necessary?” The literature 
answers this question clearly and shows that patients 
who undergo both right and left atrial lesions have better 
outcomes. Barnett and Ad performed a meta-analysis of 
the published literature up to 2006 that included 69 articles 
and 5,885 patients who had undergone either concomitant 
surgery or stand-alone surgery for AF (44). Their 
conclusion was that bi-atrial surgical procedures were more 
effective than left-sided procedures alone in eliminating AF. 
In other words, adding the right atrial lesions improved the 
results. The most extensive articles reporting the results 
of catheter ablation, surgery or hybrid procedures for the 
treatment of AF clearly demonstrate that the long-term 
results are improved by adding the right atrial lesions to the 
left atrial lesions (7-10,27-29).
CABG patients
Patients undergoing CABG as the primary surgical 
procedure but who also have AF may present with either 
concomitant PAF or concomitant N-PAF. Until proven 
otherwise, it seems prudent to treat concomitant PAF in 
these patients. Since inducing triggers come primarily from 
the region of the pulmonary veins; thus surgical isolation 
of the pulmonary veins is a reasonable approach. Patients 
with concomitant N-PAF, however, will not benefit from 
simple pulmonary vein isolation because the N-PAF is 
dependent on the self-perpetuating macro-reentrant circuits 
in the atrium and they must be addressed. Therefore, 
these patients require a Maze procedure to attain optimal 
results. However, the surgical dilemma here is that the 
Maze procedure requires opening the left atrium, and many 
surgeons are reluctant to add this to a standard CABG 
procedure that does not require a left atriotomy. Thus, the 
decision regarding whether or not to proceed with a full 
Maze procedure in these patients is left to the discretion 
of the surgeon. It is important to remember that adding 
a Maze procedure does not increase the morbidity or 
mortality of patients undergoing a CABG procedure (35).
AVR patients
Likewise, patients undergoing AVR as the primary surgical 
procedure but who also have AF may present with either 
concomitant PAF or concomitant N-PAF. These patients 
should be handled in exactly the same manner as those 
undergoing CABG and concomitant AF surgery. If the 
patient has concomitant PAF, a pulmonary vein isolation 
is sufficient. If the patient has concomitant N-PAF, the 
surgeon is faced with the same dilemma as mentioned above 
in regards to whether or not to open the left atrium in order 
to perform a full Maze procedure.
Mitral valve surgery patients
Since the left atrium has to be opened to perform mitral 
valve repair or replacement, all patients with either type 
of concomitant AF (PAF or N-PAF) should undergo a full 
Maze procedure.
It is worth mentioning that the most experienced 
arrhythmia surgeons prefer to perform a full Maze 
procedure for any type of AF in all patients undergoing 
CABG, aortic valve, or mitral valve surgery and the author 
supports that approach.
Surgical technique for isolating the pulmonary 
veins
The term “pulmonary vein isolation” can be confusing in 
that it refers to any one of three different procedures. The 
first is one in which the individual pulmonary veins are 
isolated. This is the type of “pulmonary vein isolation” that 
is done with devices like the Arctic Front catheter balloon 
(45,46). The second type of “pulmonary vein isolation” is 
one in which the right and left pulmonary veins are isolated 
in pairs. This is typically done when bipolar radiofrequency 
clamps are used (47-49). The third type of “pulmonary 
vein isolation” is one in which all four pulmonary veins as 
well as the intervening portion of the posterior LA wall are 
encompassed by one large encircling lesion, the so-called 
“box lesion”. This is the type of pulmonary vein isolation 
that is used in all iterations of the Maze procedure (5,50,51). 
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As one moves from isolating the individual pulmonary 
veins, to isolating them in pairs, to isolating all of them as a 
single unit, the results get progressively better (51).
Surgical technique for the Maze-IV procedure
Since this is not a surgical atlas; the step-by-step surgical 
technique of the current iteration of the Maze procedure, 
the Maze-IV procedure, will not be presented. However, 
a few pertinent points regarding surgical technique are 
warranted.
The left atrial portion of the Maze-IV procedure 
includes isolation of the pulmonary veins plus two linear 
lesions, a coronary sinus lesion and closure of the left atrial 
appendage. The two linear lesions are the so-called “mitral 
line” to block conduction across the left atrial isthmus 
between the inferior pulmonary veins and the mitral valve 
annulus. This mitral line in the atrial myocardium will 
fail to block conduction across the left atrial isthmus in 
approximately 15% of patients unless it is accompanied 
by a cryolesion in the coronary sinus in the same plane 
as the mitral line (1,5,50,52). The second linear lesion is 
placed from the left atrial appendage to the left superior 
pulmonary vein to preclude macro-reentry around the base 
of the appendage.
The right atrial lesions consist of: (I) a superior vena 
cava—inferior vena cava (SVC-IVC) “intercaval” lesion; 
(II) a “T” lesion from the intercaval lesion across the right 
atrial free-wall to the level of the tricuspid annulus; and (III) 
a “lateral right atrial lesion” from the “T” lesion to the tip 
of the right atrial appendage (53). These three lesions can 
be placed in a matter of minutes during the reperfusion/
rewarming phase of the operation after the left atrial lesions 
have been performed under cardioplegic arrest. Thus, they 
do not add to the cross-clamp time, the pump time or the 
overall time of the operation. 
The left atrial appendage
AF itself rarely kills patients; strokes due to AF kill 
patients. Most strokes due to AF have their origin in the 
trabeculated portions of the left atrial appendage (54). Oral 
anticoagulation therapy for the prophylaxis of strokes 
associated with AF is less than optimal and difficult to 
manage clinically (55-58). Several safe and effective 
percutaneous (59-61) and surgical methods (62,63) for 
closing the LA appendage have now been developed 
and will hopefully be fully approved by the FDA in the 
near future. These new devices and techniques have the 
capability of drastically reducing the number of strokes 
associated with AF. 
The ACC/AHA Guidelines for the Management 
of Patients with Valvular Heart Disease recommend 
amputation of the LA appendage at the time of mitral 
valve surgery to reduce the incidence of subsequent 
thromboembolic events (64). Moreover, the AHA/ACC/
ECS Guidelines for the Management of Patients with Atrial 
Fibrillation recommend surgical LA appendage closure 
in cardiac surgical patients “…who are at risk of developing 
postoperative AF” (65). These consensus recommendations 
in relatively small, highly-selected groups of patients 
are clearly based on recognition of the importance of 
the LA appendage in the genesis of strokes associated 
with AF. However, they beg the question of whether 
similar recommendations should be made to close the 
LA appendage in the millions of patients in the general 
population who have AF.
Our own experience with the surgical treatment of 
AF suggests that removal or proper closure of the LA 
appendage at the time of surgery reduces the risk of early 
perioperative strokes dramatically and nearly eliminates the 
risk of subsequent long-term stroke (66). The incidence 
of perioperative stroke is 3.2% following CABG, 2.8% 
following valve surgery and 6.7% following CABG plus 
valve surgery (67). However, in our experience when a Maze 
procedure for AF was performed either as a “stand-alone” 
procedure or was added to these other surgical operations as 
a “concomitant” procedure, the incidence of perioperative 
stroke dropped to less than 1% (68). This observation is 
particularly surprising in view of the fact that nearly 20% 
of the patients in our series had a history of at least one 
systemic thromboembolic event prior to their surgery, 
putting them at an even higher risk for perioperative stroke. 
The critical part of the Maze procedure that decreases 
perioperative stroke, and by inference the long-term stroke 
rate, is closure of the LA appendage.
The previous difficulty in attaining complete appendage 
closure by surgical suturing or stapling (69) has been largely 
overcome by the recent introduction of external clips that 
can be positioned quickly and easily near the base of the LA 
appendage during surgery. The device most commonly used 
is the AtriClip (Atricure, Inc., West Chester, Ohio, USA), 
which is designed so that the inherent expansive force 
exerted by the nitinol is directed centrally from both sides 
of the clip in order to apply a constant dynamic pressure 
to the base of the LA appendage, thereby keeping it closed 
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permanently (63). This external clip not only closes the LA 
appendage effectively but it also interrupts the myocardial 
blood supply of the appendage itself, resulting in its 
gradual disappearance. In the multicenter FDA-approved 
EXCLUDE trial, the LA appendage was closed successfully 
with the AtriClip device in 98.4% of patients with no 
device-related mortality (63).
The LA appendage has been accurately termed “our 
most lethal human attachment” (70) and we are now obliged 
to consider its mechanical closure in a larger spectrum of 
the population. Certainly, the LA appendage should be 
closed in every patient with AF who enters our operating 
rooms. Indeed, it is not unreasonable to consider closing the 
LA appendage in all patients undergoing cardiac surgery, 
though a prospective, randomized trial would be essential to 
proving the validity of that practice.
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